Search

Organoid Culture Compositions and Methods from Cryogenically Preserved Tissue

USPTO granted patent US12600953B2 to The Regents of the University of Michigan on April 14, 2026. The patent covers compositions and methods for establishing organoid cultures from cryogenically preserved tissue (e.g., human biopsy tissue), along with related methods of use. The application (No. 16634818) was filed on July 27, 2018, with eight claims allowed.

Method of Generating Multipotent Stem Cells (Patent US12600950B2)

The USPTO granted Patent US12600950B2 to The Trustees of Columbia University in the City of New York for a method of generating multipotent stem cells. The invention involves delivering reprogramming proteins called Master Regulator (MR) proteins—including BAZ2B, ZBTB20, ZMAT1, CNOT8, KLF12, DMTF1, HBP1, or FLI1—into somatic cells to produce and/or expand multipotent stem cells. The patent application was filed March 31, 2023, and contains 7 claims.

Translate Bio mRNA Synthesis Patent (US12600998B2)

USPTO granted patent US12600998B2 to Translate Bio, Inc. on April 14, 2026. The patent covers methods for large-scale production of full-length messenger RNA (mRNA) substantially free of double-stranded RNA using in vitro transcription with SP6 RNA polymerase. The patent contains 19 claims and was filed as application 17502816.

Modified Immune Cells with Adenosine Deaminase Base Editors for Gene Editing

USPTO granted Patent US12600971B2 to Beam Therapeutics Inc. covering genetically modified immune cells incorporating adenosine base editors (ABE8) for modifying nucleobases in target sequences. The patent contains 22 claims and was filed on February 13, 2020, under Application No. 17430676.

Expression Control Using a Regulatable Intron

The USPTO granted patent US12600969B2 to Askbio Inc. on April 14, 2026, covering gene expression regulation using regulatory nucleic acid sequences responsive to the unfolded protein response (UPR). The patent includes 14 claims for regulatable introns and UPR-inducible promoters in recombinant expression constructs. This patent grant does not create compliance obligations.

Dexcom G7 iOS CGM App Type II Recall - Display Flicker Issue

Health Canada issued a Type II medical device recall for Dexcom G7 iOS CGM App versions 2.9.0 to 2.11.2 (model SW12300). The affected apps display a flicker that sequentially shows previous Estimated Glucose Values before displaying the current reading. Users are advised to contact Dexcom, Inc. for additional information. The recall was published April 14, 2026, with recall date April 9, 2026.

Nitrous Oxide Chargers: Sold for Inhalation Without Market Authorization

Health Canada has issued a Type I recall for PUR GAS Cream Charger nitrous oxide products sold without Drug Identification Number (DIN) market authorization. The products, sold in multiple flavours including Blue Raspberry, Mango, and Grape, were marketed for inhalation purposes. Posh Glass Inc. of Calgary, Alberta is the affected company. Retailers are required to remove these products from the Canadian market.

Revolution Ascend CT Security Vulnerability Recall

Health Canada issued a Type II medical device recall for GE Healthcare Japan Corporation's Revolution Ascend CT systems due to a potential security vulnerability in the AW server deployed via Edison Health Link (EHL) based CT smart subscription. Three lots are affected: AS10G2400087YC, AS10G2400056YC, and AS10G2400081YC, all with model/catalogue number 00840682146173. Healthcare providers using these devices should contact the manufacturer for additional information regarding the cybersecurity vulnerability.

Good Brain Tonic Recalled by Liquid Blenz Corp Due to Botulism Risk

Liquid Blenz Corp of Rockville Center, NY is recalling all codes of Good Brain Tonic (16 oz and 32 oz amber bottles) due to potential botulism contamination. The contamination was discovered through analysis by Cornell Food Venture Center and field testing by New York State Department of Agriculture and Markets Food Inspectors. The product was distributed nationwide through retail stores and internet sales. No illnesses have been reported to date.

Nucleic Acid Complexes with Cationic/Anionic Polymers and RNA Molecules

The USPTO published patent application US20260096998A1 for nucleic acid complexes comprising cationic polymers, anionic polymers, and monomeric RNA molecules. The disclosed complexes feature a core structure where the cationic polymer and RNA molecule are encapsulated by the anionic polymer. The application covers linear and non-linear configurations of these complexes for therapeutic uses.